文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗S-268019-a在啮齿类动物的临床前研究及日本成人中的1/2期随机双盲安慰剂对照平行组研究结果

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
PubMed 文献 · Vaccine · 2022-12-16

S-268019-a为含agatolimod sodium佐剂的重组刺突蛋白疫苗。小鼠中安全并诱导强IgG和中和抗体,攻毒后全部存活而对照全死;日本健康成人1/2期试验中耐受良好、安全至第50天并诱导强抗刺突IgG,但未诱导足够中和抗体水平。

要点

  • 小鼠中S-268019-a安全并诱导强IgG和中和抗体,攻毒后全部存活。
  • 日本成人中耐受良好、安全至第50天,诱导强抗刺突IgG抗体。
  • 日本成人中未诱导足够的中和抗体水平,免疫原性不足。

核心结论

  • S-268019-a疫苗在日本成人中免疫原性不足,尽管在小鼠中具有强免疫原性和效力。
  • 结果例证了将动物临床前数据转化至临床试验的固有挑战,并强调需继续研究以克服此类障碍。

研究设计与样本

  • 临床前阶段:7周龄小鼠肌内注射两次,间隔2周。
  • 临床阶段:1/2期随机双盲安慰剂对照平行组研究,健康成人(20-64岁)。
  • 所有参与者肌内注射两次,间隔3周,抗原/佐剂组合为S-910823/agatolimod sodium(μg:12.5/250、25/250、50/250、25/500、50/500、100/500、10/500、100/100、200/1000)或等体积安慰剂(生理盐水)。
  • 本次 interim 分析随访至第50天。

主要发现

  • 临床前研究中S-268019-a安全,在小鼠中诱导强IgG和中和抗体应答。
  • SARS-CoV-2攻毒后,所有S-268019-a处理小鼠存活并维持体重至10天,而所有安慰剂或仅佐剂处理(无抗原)小鼠在6天内死亡。
  • 1/2期试验中S-268019-a在成人参与者中耐受良好、安全至第50天,并诱导强抗刺突蛋白IgG抗体。
  • 1/2期试验中S-268019-a未诱导足够的中和抗体水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In early 2020, developing vaccines was an urgent need for preventing COVID-19 from a contingency perspective. METHODS: S-268019-a is a recombinant protein-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising a modified recombinant spike protein antigen adjuvanted with agatolimod sodium, a Toll-like receptor-9 agonist. In the preclinical phase, it was administered intramuscularly twice at a 2-week interval in 7-week-old mice. Immunogenicity was assessed, and the mice were challenged intranasally with mouse-adapted SARS-CoV-2 at 2 and 8 weeks, respectively, after the second immunization. After confirming the preclinical effect, a Phase 1/2, randomized, parallel-group clinical study was conducted in healthy adults (aged 20-64 years). All participants received 2 intramuscular injections at various combinations of the antigen and the adjuvant (S-910823/agatolimod sodium, in μg: 12.5/250, 25/250, 50/250, 25/500, 50/500, 100/500, 10/500, 100/100, 200/1000) or placebo (saline) in an equivalent volume at a 3-week interval and were followed up until Day 50 in this interim analysis. RESULTS: In the preclinical studies, S-268019-a was safe and elicited robust immunoglobulin G (IgG) and neutralizing antibody responses in mice. When challenged with SARS-CoV-2, all S-268019-a-treated mice survived and maintained weight until 10 days, whereas all placebo- or adjuvant-treated (without antigen) mice died within 6 days. In the Phase 1/2 trial, although S-268019-a was well tolerated in adult participants, was safe up to Day 50, and elicited robust anti-spike protein IgG antibodies, it did not elicit sufficient neutralizing antibody levels. CONCLUSIONS: The S-268019-a vaccine was not sufficiently immunogenic in Japanese adults despite robust immunogenicity and efficacy in mice. Our results exemplify the innate challenges in translating preclinical data in animals to clinical trials, and highlight the need for continued research to overcome such barriers. (jRCT2051200092).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sonoyama T, Iwata S, Shinkai M, et al. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 2022. PMID: 36572603. doi:10.1016/j.vaccine.2022.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。